INDIVIOR PHARMACEUTICALS INC

Indivior Surges: Q2 2026 Results Beat Expectations, Upgrades 2026 Guidance, and Announces Merger with Supernus

Indivior’s Q2 2026 results beat expectations, lifting full‑year guidance and announcing a merger with Supernus to broaden CNS therapy and drive growth.

INDIVIOR PHARMACEUTICALS INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

03/08/2026, 12:41

2 minutes to read

Indivior Raises EPS Forecast, Projects Modest Revenue Growth for FY2026

Indivior Pharmaceuticals reports stronger Q1 EPS, upbeat outlook, but modest revenue growth. Learn how strategic cost cuts boost shareholder value in a volatile market.

INDIVIOR PHARMACEUTICALS INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

30/04/2026, 13:08

2 minutes to read